Original research article
Porto Biomed. J. 2017; 2(5): 170-173 doi: http://dx.doi.org/doi:10.1016/j.pbj.2017.03.007 (Published 2 May 2017)

Neoadjuvant endocrine therapy in breast cancer patients

Raquel Lobo-Cardosoa,*, André Torres Magalhãesb, José Luís Fougob

Faculty of Medicine, University of Porto, Porto, Portugal
Breast Center, General Surgery Service, São João Hospital, Porto, Portugal
*Corresponding author:
Accepted 25 March 2017
Background: The aim of this study is to evaluate if the extension of neoadjuvant endocrine therapy (NET), beyond the conventional time, allows additional downstage of the tumour, in order to perform a breast conservative surgery (BCS), and to analyze if it is a good option for long-term control in patients who refuse or are unfit for surgery. Patients and methods: We retrospectively reviewed a database containing all patients treated in our institution with NET. All included patients were post-menopausal with primary local disease. The type of response obtained was assessed using modified RECIST criteria. Results: Thirty-three patients were included. Two patients had tumours with 90% expression of oestrogen receptors and all the others had 100%. The tumour size in the largest diameter was 6.51 cm before treatment and 5.18 cm after. Eighteen patients achieved a partial response after 10.28 months of therapy. Patients that were proposed to downstage the tumour performed 9.71 months of therapy until surgery and all were submitted to BCS. Progression occurred after 27.5 months. Conclusion: Endocrine therapy is a feasible option for a longer time to allow additional downstage of the tumour and is a good solution in patients who refuse or are unfit for surgery.
Breast cancer; Neoadjuvant treatment; Endocrine therapy; Estrogen receptor-positive; Breast conserving surgery
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.